Virtual and in vitro screens reveal a potential pharmacophore that avoids the fibrillization of Aβ1-42

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Hernández Rodríguez, Maricarmen ^a   Correa Basurto, José ^a   Nicolás Vázquez, María Inés ^b   Miranda Ruvalcaba, René ^b   Benítez Cardoza, Claudia Guadalupe ^a   Reséndiz Albor, Aldo Arturo ^a   Méndez Méndez, Juan Vicente ^a   Rosales Hernández, Martha C ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-42] INHIBITOR; AROMATIC COMPOUND; OLIGOMER; PROTEIN INHIBITOR; TERTIARY AMINE; UNCLASSIFIED DRUG; AMINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); LIGAND; MOLECULAR LIBRARY; PEPTIDE FRAGMENT;

ALPHA HELIX; ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING AFFINITY; CIRCULAR DICHROISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; IN VITRO STUDY; MOLECULAR DOCKING; PHARMACOPHORE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; VIRTUAL REALITY; CHEMISTRY; COMPUTER INTERFACE; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PRECLINICAL STUDY; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; THERMODYNAMICS;

AMINES; AMYLOID BETA-PEPTIDES; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; SMALL MOLECULE LIBRARIES; THERMODYNAMICS; USER-COMPUTER INTERFACE;

EID: 84940707249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130263     Document Type: Article

References (58)

1. Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol. 1984; 2: 357-369. PMID: 6242724
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991; 6: 487-498. PMID: 1673054
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297: 353-356. PMID: 12130773
4. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010; 6: 99-107. doi: 10.1038/nrneurol.2009.218 PMID: 20139999
5. Sciarretta KL, Gordon DJ, Petkova AT, Tycko R, Meredith SC. Abeta40-Lactam (D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry. 2005; 44: 6003-6014. PMID: 15835889
6. Kirkitadze MD, Condron MM, Teplow DB. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol. 2001; 312: 1103-1119. PMID: 11580253
7. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002; 30: 552-557. PMID: 12196135
8. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998; 95: 6448-6453. PMID: 9600986
9. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416: 535-539. PMID: 11932745
10. LeVine H III. Small molecule inhibitors of Abeta assembly. Amyloid. 2007; 14: 185-197. PMID: 17701466
11. Salomon AR, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry. 1996; 35: 13568-13578. PMID: 8885836
12. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem. 1998; 273: 7185-7188. PMID: 9516407
13. Mason JM, Kokkoni N, Stott K, Doig AJ. Design strategies for anti-amyloid agents. Curr Opin Struct Biol. 2003; 13: 526-532. PMID: 12948784
14. Orlando RA, Gonzales AM, Royer RE, Deck LM, Vander Ja DL. A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization. PLoS One. 2012; 7, e31869. doi: 10.1371/journal.pone.0031869 PMID: 22442659
15. Shaw JE, Chio J, Dasgupta S, Lai AY, Mo GC, Pang F, et al. Aβ (1-42) Assembly in the presence of scyllo-inositol derivatives: identification of an oxime linkage as important for the development of assembly inhibitors. ACS Chem Neurosci. 2012; 3: 167-177. doi: 10.1021/cn2000926 PMID: 22860186
16. Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, et al. Interaction of the anthracycline 4′-iodo-4-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci USA. 1995; 92: 2959-2963. PMID: 7708755
17. Esteras-Chopo A, Morra G, Moroni E, Serrano L, Lopez de la Paz M, Colombo G. A molecular dynamics study of the interaction of D-peptide amyloid inhibitors with their target sequence reveals a potential inhibitory pharmacophore conformation. J Mol Biol. 2008; 383: 266-280. doi: 10.1016/j.jmb.2008.07.076 PMID: 18703072
18. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature. 2003; 426: 905-909. PMID: 14685252
19. Landau M, Sawaya MR, Faull KF, Laganowsky A, Jiang L, Sievers SA, et al. Towards a pharmacophore for amyloid. PLoS. Biol. 2011; 9: e1001080. doi: 10.1371/journal.pbio.1001080 PMID: 21695112
20. Nerelius C, Sandegren A, Sargsyan H, Raunak R, Leijonmarck H, Chatterjee U, et al. α-Helix targeting reduces amyloid-β peptide toxicity. Proc Natl Acad Sci USA. 2009; 106: 9191-9196. doi: 10.1073/pnas.0810364106 PMID: 19458258
21. Ito M, Johansson J, Strömberg R, Nilsson L. Unfolding of the amyloid b-peptide central helix: mechanistic insights from molecular dynamics simulations. PLoS One. 2011; 3: 1-13.
22. Bansode SB, Jana AK, Batkulwar KB, Warkad SD, Joshi RS, Sengupta N, et al. Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease. PLoS One. 2014; 9: e105196. doi: 10.1371/journal.pone.0105196 PMID: 25141174
23. Cui L, Zhang Y, Cao H, Wang Y, Teng T, Ma G, et al. Ferulic acid inhibits the transition of amyloid-β42 monomers to oligomers but accelerates the transition from oligomers to fibrils. J Alzheimers Dis. 2013; 37: 19-28. doi: 10.3233/JAD-130164 PMID: 23727899
24. Aloisi A, Barca A, Romano A, Guerrieri S, Storelli C, Rinaldi R, et al. Anti-aggregating effect of the naturally occurring dipeptide carnosine on aβ1-42 fibril formation. PLoS One. 2013; 8: e68159. doi: 10.1371/journal.pone.0068159 PMID: 23844165
25. Singh SK, Gaur R, Kumar A, Fatima R, Mishra L, Srikrishna S. The flavonoid derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one protects against Aβ42-induced neurodegeneration in transgenic Drosophila: insights from in silico and in vivo studies. Neurotox Res. 2014; 26:331-350 doi: 10.1007/s12640-014-9466-z PMID: 24706035
26. Hernández-Rodríguez M, Correa-Basurto J, Benitez-Cardoza CG, Resendiz-Albor AA, Rosales-Hernández MC. In silico and in vitro studies to elucidate the role of Cu2+ and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process. Protein Sci. 2013; 22: 1320-1335. doi: 10.1002/pro.2319 PMID: 23904252
27. Frishman D, Argos P. Knowledge-Based Protein Secondary Structure Assignment. Proteins. 1995; 23: 566-579. PMID: 8749853
28. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Computat Chem.1998; 19: 1639-1662.
29. G Dewar MJ, Zoebish EG, Healey EF, Stewart JP. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985; 107: 3902.
30. Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010; 24: 417-422. doi: 10.1007/s10822-010-9352-6 PMID: 20401516
31. Levine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993; 2: 404-410. PMID: 8453378
32. Sreerama N, Woody RW. A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal Biochem. 1993; 209: 32-44. PMID: 8465960
33. Perez-Iratxeta C, Andrade-Navarro MA. K2D2: Estimation of protein secondary structure from circular dichroism spectra. BMC Struct Biol. 2008; 8: 25. doi: 10.1186/1472-6807-8-25 PMID: 18477405
34. Fukui K. Role of frontier orbitals in chemical reactions. Science. 1982; 218: 747-754. PMID: 17771019
35. Politzer P, Laurence PR, Jayasuriya K. Molecular Electrostatic Potentials: An Effective Tool for the Elucidation of Biochemical Phenomena. Environ Health Perspect. 1985; 61: 191-202. PMID: 2866089
36. Hehre WJ, Shusterman AJ, Nelson JE. The Molecular Modeling Workbook for Organic Chemistry, Wavefunction, Inc. 1998. 18401 Von Karman Ave., Suite 370 Irvine, CA 92612, pp 29-31 and 50-51.
37. Hunter CA. Quantifying intermolecular interactions: guidelines for the molecular recognition toolbox Angew. Chem Int. 2004. Ed. 43, 5310-5324.
38. Fezoui Y, Teplow DB. Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J Biol Chem. 2002; 277: 36948-36954. PMID: 12149256
39. Wheeler SE, Houk KN. Through-space effects of substituents dominate molecular electrostatic potentials of substituted arenes. J Chem Theor Comput. 2009; 5: 2301-2312.
40. Chebaro Y, Jiang P, Zang T, Mu Y, Nguyen PH, Mousseau N, et al. Structures of Aβ17-42 trimers in isolation and with five small-molecule drugs using a hierarchical computational procedure. J Phys Chem B. 2012; 116: 8412-8422. doi: 10.1021/jp2118778 PMID: 22283547
41. Xie Q, Wang H, Xia Z, Lu M, Zhan W, Wang X, et al. Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008; 51: 2027-2036. doi: 10.1021/jm070154q PMID: 18333606
42. Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev. 2010; 64: 328-363. doi: 10.1016/j.brainresrev.2010.05.003 PMID: 20685221
43. Doig AJ, Derreumaux P. Inhibition of protein aggregation and amyloid formation by small molecules. Curr Opin Struct Biol. 2015; 30: 50-56. doi: 10.1016/j.sbi.2014.12.004 PMID: 25559306
44. Nasica-Labouze J, Nguyen PH, Sterpone F, Berthoumieu O, Buchete NV, Coté S, et al. Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies. Chem Rev. 2015; 115: 3518-3563 doi: 10.1021/cr500638n PMID: 25789869
45. Tarus B, Nguyen PH, Berthoumieu O, Faller P, Doig AJ, Derreumaux P. Molecular structure of the NQTrp inhibitor with the Alzheimer Aβ1-28 monomer. Eur J Med Chem. 2015; 91: 43-50. doi: 10.1016/j.ejmech.2014.07.002 PMID: 25011560
46. Novick PA, Lopes DH, Branson KM, Esteras-Chopo A, Graef IA, Bitan G, et al. Design of β-amyloid aggregation inhibitors from a predicted structural motif. J Med Chem. 2012; 55: 3002-3010. doi: 10.1021/jm201332p PMID: 22420626
47. Matsubara E, Takamura A, Okamoto Y, Oono H, Nakata T, Wakasaya Y, et al. Disease modifying therapies for Alzheimer's disease targeting a β oligomers: implications for therapeutic mechanisms. Biomed Res Int. 2013; 2013: 984041. doi: 10.1155/2013/984041 PMID: 24063020
48. Li J, Yang JY, Yao XC, Xue X, Zhang QC, Wang XX, et al. Oligomeric Aβ-induced microglial activation is possibly mediated by NADPH oxidase. Neurochem Res. 2013; 38: 443-452. doi: 10.1007/s11064-012-0939-2 PMID: 23229789
49. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999; 155: 853-862. PMID: 10487842
50. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002; 277: 32046-32053. PMID: 12058030
51. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003; 43: 545-584. PMID: 12415125
52. Chen WT, Liao YH, Yu HM, Cheng IH, Chen YR. Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabilization promotes annular protofibril formation. J Biol Chem. 2011; 286: 9646-9656. doi: 10.1074/jbc.M110.177246 PMID: 21216965
53. Zhang T, Xu W, Mu Y, Derreumaux P. Atomic and dynamic insights into the beneficial effect of the 1,4-naphthoquinon-2-yl-L-tryptophan inhibitor on Alzheimer's Aβ1-42 dimer in terms of aggregation and toxicity. ACS Chem Neurosci. 2014; 5: 148-159. doi: 10.1021/cn400197x PMID: 24246047
54. Nguyen P, Derreumaux P. Understanding amyloid fibril nucleation and aβ oligomer/drug interactions from computer simulations. Acc Chem Res. 2014; 47:603-611. doi: 10.1021/ar4002075 PMID: 24368046
55. Yadav A, Sonker M. Perspectives in designing anti aggregation agents as Alzheimer disease drugs. Eur J Med Chem. 2009; 44: 3866-3873. doi: 10.1016/j.ejmech.2009.04.013 PMID: 19497645
56. Pohl G, Plumley JA, Dannenberg JJ. The interactions of phenylalanines in β-sheet-like structures from molecular orbital calculations using density functional theory (DFT), MP2, and CCSD(T) methods. J Chem Phys. 2013; 138: 245102. doi: 10.1063/1.4811712 PMID: 23822281
57. Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, et al. Amitriptyline-mediated cognitive enhancement in aged 3xTg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS One. 2011; 6: e21660. doi: 10.1371/journal.pone.0021660 PMID: 21738757
58. Matharu B, Gibson G, Parsons R, Huckerby TN, Moore SA, Cooper LJ, et al. Galantamine inhibits b-amyloid aggregation and cytotoxicity. J Neurol Sci. 2009; 280: 49-58. doi: 10.1016/j.jns.2009.01.024 PMID: 19249060